InterK Peptide Therapeutics is a preclinical biotechnology company developing immune-boosting synthetic peptides to treat cancer, UV-induced skin damage, and to act as an alternative to opioid analgesics.

In addition to their potential use as adjuvants in vaccination strategies and in enhancing DNA repair following ultraviolet irradiation, InterK’s lead compound, IK14004, influences the functionality of human immune cells in a manner that suppresses cancer growth without compromising immune tolerance to the body’s own proteins, thereby avoiding the promotion of autoimmunity.

Importantly, these immunomodulatory effects of IK14004 are also relevant to the immune dysfunction underlying endometriosis, an area of intense investigation by InterK Peptide Therapeutics Ltd.